🔗 Share this article

While the United States undertakes historic revisions to its vaccination recommendations, one figure appears somewhat surprisingly: Høeg, an American of Danish descent sports medicine doctor and epidemiologist who rose to prominence by expressing skepticism about COVID-19 vaccinations throughout the pandemic and has focused upon alleged deaths after Covid immunization in her short time at the Food and Drug Administration.

Planned Shifts to Pediatric Immunization Program

Agency leaders were set to unveil major revisions to the childhood immunization program earlier this month, aligning the US with Denmark’s vaccine program, it is understood – a major change that would put the US out of alignment with a large portion of the international standard with no evidence for benefit. The planned update has been delayed until the coming year.

In place of Vinay Prasad, Høeg is set to address the audience at the gathering. She was recently named interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to lead the office this year.

A New Direction at the Agency

The acting appointment could signify a strengthened alliance between the pharmaceutical and vaccine centers as Dr. Høeg and Dr. Prasad strengthen their influence at the regulatory agency – and it suggests a renewed priority upon rolling back previously authorized immunizations at the FDA.

Dr. Høeg has repeatedly called for discontinuing some pediatric immunization guidelines in the US in order to be more similar to Denmark's approach, a society with nationalized medicine and a citizenry roughly the population of Wisconsin’s.

So far public appearances, she has kept her attention on immunizations – usually the purview of Dr. Prasad, chief of the FDA’s vaccine center – as opposed to drug regulation.

Doubts Over Qualifications

The appointee has little discernible track record in medication creation, approval processes or management, which has been customary for past leaders of the biologics center. She has worked at the FDA as a key advisor to the FDA chief and CBER since earlier this year.

“It seems she lacks to have the requisite experience” for running the drug-regulation department, remarked Jonathan Howard. “She lacks experience running a clinical trial. She is not versed in running a sizeable institution. She has no expertise in pharmaceutical oversight.”

Former commissioners of CBER would “understand laws and regulations and the underlying principles of drug development”, noted a former acting FDA commissioner. “Clearly, she lacks the type of experience that prior appointees who headed CBER have had.”

The drug center has an immense range of responsibilities at the agency, she stated.

“Everybody just zeroes in on the new drug program, but the generic program authorizes a multitude of off-brand pharmaceuticals. There’s a biosimilars division, over-the-counter program and other areas, and all of those need to be looked after,” she said. “The thing you neglect, that is the part that I always told people is going to cause problems.”

Furthermore, a significant management element to the job, which oversees in excess of 5,000 employees. “It is a huge management job, if you perform it correctly,” she concluded.

Response and Contentious Programs

Regarding inquiries about Høeg’s qualifications and whether this selection indicates increased cooperation among FDA leaders on immunizations, a press secretary stated that the “inquiries stem from flawed presumptions”.

“Her experience aligns with the functions of her job,” the spokesperson stated, pointing to the time Dr. Høeg spent advising the agency head on “drug safety and approval science, including computerized risk analysis and shot safety tracking”.

In her interim role, Dr. Høeg assumes responsibility for the commissioner’s controversial expedited review system, a contentious one-day medication authorization process that apparently troubled her former heads. “How are these medications being chosen for this expedited pathway? Who makes the decisions?” Dr. Howard questioned. “There’s a lot of confidentiality occurring at the FDA right now.”

Overall, he remarked, “the FDA seems to be moving towards laxer rules of most medications, with the exception of vaccines.”

Documented Track Record on Immunizations

With vaccines, Høeg has a more documented, if problematic, history, critics observe. She published a research paper using non-validated public submissions to assess the incidence of heart inflammation following Covid immunization. She advised the state of Florida chief medical officer Joseph Ladapo, who allegedly have altered data to imply Covid vaccines are pose a greater threat than they are.

Included in her “desired changes” for the current federal leadership featured revising rules for novel immunizations and ending “unnecessary” vaccines, she stated after the election on a audio program. At the FDA, Høeg has reportedly floated the idea of barring adolescent males from getting Covid vaccines.

“She’s an thorough dogmatist who begins with her beliefs and works backwards to accommodate the data in a very misleading, dishonest manner,” Howard stated.

Gaining Influence and a “Push for Payback”

Høeg joined fellow skeptics, {like|